Moderna (NASDAQ:MRNA) PT Lowered to $155.00 at Barclays

Moderna (NASDAQ:MRNA) had its price objective dropped by equities researchers at Barclays from $168.00 to $155.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Barclays‘s target price suggests a potential upside of 79.03% from the stock’s previous close.

A number of other equities research analysts have also commented on MRNA. Royal Bank of Canada increased their price target on Moderna from $135.00 to $160.00 and gave the company an “outperform” rating in a research report on Monday, June 3rd. Canaccord Genuity Group boosted their price target on shares of Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a report on Friday, May 3rd. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research report on Thursday, June 27th. UBS Group lifted their target price on shares of Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a report on Thursday. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, Moderna currently has a consensus rating of “Hold” and a consensus price target of $126.59.

Moderna Stock Down 8.1 %

Moderna stock opened at $86.58 on Friday. The firm has a market capitalization of $33.18 billion, a price-to-earnings ratio of -5.53 and a beta of 1.67. The firm’s fifty day moving average price is $129.81 and its two-hundred day moving average price is $115.11. Moderna has a 1-year low of $62.55 and a 1-year high of $170.47. The company has a current ratio of 4.09, a quick ratio of 3.91 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, beating the consensus estimate of ($3.47) by $0.14. The business had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm’s revenue for the quarter was down 29.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($3.62) EPS. On average, equities research analysts predict that Moderna will post -7.46 earnings per share for the current fiscal year.

Insider Transactions at Moderna

In related news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $119.96, for a total transaction of $1,799,400.00. Following the sale, the director now directly owns 2,224,015 shares in the company, valued at approximately $266,792,839.40. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, CFO James M. Mock sold 689 shares of the business’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $118.24, for a total transaction of $81,467.36. Following the completion of the transaction, the chief financial officer now directly owns 7,269 shares in the company, valued at approximately $859,486.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $119.96, for a total value of $1,799,400.00. Following the completion of the sale, the director now owns 2,224,015 shares in the company, valued at approximately $266,792,839.40. The disclosure for this sale can be found here. Insiders sold 396,239 shares of company stock valued at $55,563,937 over the last three months. Company insiders own 15.70% of the company’s stock.

Hedge Funds Weigh In On Moderna

A number of institutional investors have recently added to or reduced their stakes in MRNA. TIAA Trust National Association raised its stake in Moderna by 2.3% in the fourth quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock valued at $447,000 after purchasing an additional 102 shares in the last quarter. International Assets Investment Management LLC lifted its holdings in shares of Moderna by 6,528.9% during the 4th quarter. International Assets Investment Management LLC now owns 387,656 shares of the company’s stock worth $38,552,000 after acquiring an additional 381,808 shares during the last quarter. Allworth Financial LP lifted its holdings in shares of Moderna by 6.5% during the 4th quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock worth $165,000 after acquiring an additional 101 shares during the last quarter. Cadinha & Co. LLC grew its position in Moderna by 109.0% in the fourth quarter. Cadinha & Co. LLC now owns 81,838 shares of the company’s stock worth $8,139,000 after acquiring an additional 42,685 shares in the last quarter. Finally, Stratos Wealth Advisors LLC increased its stake in Moderna by 32.3% in the fourth quarter. Stratos Wealth Advisors LLC now owns 4,003 shares of the company’s stock valued at $398,000 after acquiring an additional 978 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.